Results for the Quarter/ Half Year ended 30/09/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd reported total revenue of Rs 498.22 lakhs in Q2 FY26 (down from Rs 588.86 lakhs in Q2 FY25) with a profit after tax of Rs 7.18 lakhs versus Rs 23.60 lakhs in the year-ago quarter. For H1 FY26, total revenue grew sharply to Rs 1,087.08 lakhs from Rs 736.21 lakhs in H1 FY25, a jump of about 48%. The company swung to a half-yearly profit of Rs 30.78 lakhs compared with a loss of Rs 47.18 lakhs in H1 FY25. Total expenses stood at Rs 1,056.34 lakhs for H1 FY26. The statutory auditor (Rajiv Udai & Associates) issued an unmodified limited review report with no qualifications or emphasis of matter.
The sharp swing from loss to profit and strong H1 revenue growth are positive signals for shareholders, though the sequential Q2 slowdown in revenue and PAT suggests the H1 performance may be lumpy. No audit concerns were flagged.